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ABSTRACT
Adherence to antiretroviral therapy (ART) prevents disease progression, and the emergence of resistant 
mutations. It also reduces morbidity, and the necessity for more frequent, complicated regimens which 
are also relatively more expensive. Minimum adherence levels of 95% are required for treatment success. 
Poor adherence to treatment remains a stumbling block to the success of treatment programs. This 
generates major concerns about possible resistance of the human immunodeficiency virus (HIV) to the 
currently available ARVs. This paper aims to describe baseline results from a cohort of 242 Malaysian 
patients receiving ART within the context of an intervention aimed to improve adherence and treatment 
outcomes among patients initiating ART.
A single-blinded Randomized Controlled Clinical Trial was conducted between January and December, 
2014 in Hospital Sungai Buloh. Data on socio-demographic factors, clinical symptoms and adherence 
behavior of respondents was collected using modified, pre-validated 
Adult AIDS Clinical Trials Group (AACTG) adherence questionnaires. Baseline CD4 count, viral load, 
weight, full blood count, blood pressure, Liver function and renal profile tests were also conducted and 
recorded. Data was analyzed using SPSS version 22 and R software.
Patients consisted of 215 (89%) males and 27 (11%) females. 117 (48%) were Malays, 98 (40%) were 
Chinese, 22 (9%) were Indians while 5 (2%) were of other ethnic minorities. The mean age for the 
intervention group was 32.1 ± 8.7 years while the mean age for the control group was 34.7 ± 9.5 years. 
Mean baseline adherence was 80.1 ± 19.6 and 85.1 ± 15.8 for the intervention and control groups 
respectively. Overall mean baseline CD4 count of patients was 222.97 ± 143.7 cells/mm³ while overall 
mean viral load was 255237.85 ± 470618.9. Patients had a mean weight of 61.55 ± 11.0 kg and 61.47 ± 
12.3 kg in the intervention and control groups, respectively. 
Males account for about 90% of those initiating ART in the HIV clinic, at a relatively low CD4 count, 
high viral load and sub-optimal medication adherence levels at baseline.   
 
Keywords: Adherence, Antiretroviral Therapy (ART), HIV/AIDS, CD4 count, Viral load, 
treatment outcomes.
INTRODUCTION
HIV was first diagnosed in Malaysia in 1986. By the end of 2013, there was a cumulative figure of 101,672   HIV 
cases reported to the Ministry of Health, 20,235 AIDS cases, and 16,340 deaths.1 In 2002, the epidemic peaked with 
a rate of 28.5 per 100,000 population. Since then, there has been a steady decline achieved at a rate of 11.42 per 
100,000 population in 2013.1   By 2013, the number of persons living with HIV/AIDS increased to 86,324 with 3,393 
new infections in the same year. The introduction of harm reduction programs since 2005 has resulted in a significant 
decline in the number of HIV infections through needle sharing. However, in recent years, there is increasing evidence 
that overlapping of injecting drug use (IDU) and risky sex behavior is occurring, resulting in increased HIV infection 
between the different populations. In 2011, sexual transmission had superseded IDU as the key driving factor of the 
epidemic with a ratio of 6 sexual transmissions for every 4 IDU reported.2   There is a significant changing trend in 
HIV by gender with a male: female ratio of 9.6:1 in 2000 to 3.7:1 by 2013.1   The incidence rate of HIV infection 
among adults 15-49 years old has decreased from 49% to 26% between 2001 and 2011.3  Malaysia with an overall 
HIV prevalence of 0.5% and a concentrated epidemic, has about 17,369 patients as at the end of 20131 for which the 
Malaysian Government currently almost entirely provides all the funds for HIV treatment care and support for, at no 
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cost to the patients on first line medications and heavily subsidized for those on second line antiretrovirals (ARVs). 
However, the unmet need for Antiretroviral Therapy (ART) is estimated to be 50 – 60%. Despite these efforts, the 
globally recognized issues of injecting drug use, stigma and discrimination as well as poor adherence to treatment 
(clinic visits and medication adherence) remains a stumbling block to the success of treatment programs and generates 
major concerns about resistance of the HIV virus to the currently available ARVs.
Adherence to ARVs prevents disease progression, and the emergence of resistant mutations, thereby reducing 
morbidity, and the necessity for more frequent, complicated regimens which are also relatively more expensive. 
According to WHO (2005), minimum adherence levels of 95% are required for treatment success.4-7 Other studies 
have demonstrated that ARV medication adherence levels of 54 – 95% is required to maintain prolonged viral load 
suppression depending on the allowable flexibility margins of each ART program. It is however generally accepted 
that those patients who adhere strictly to their medication achieve viral suppression, while those who are not adherent 
may not.5-8   Poor adherence is a significant cause of treatment failure, disease progression and death among HIV 
patients. Once treatment failure results from poor adherence, the preventive opportunity that antiretroviral treatment 
provides is lost. Poor adherence also has grave socioeconomic impact on program funding, as more patients who 
fail on first line regimens have to be provided with the more expensive and complex second line medications.3,9 
Several studies have identified stigma and discrimination, pill burden, disclosure issues, depression, medication side 
effects, drug and alcohol use, unemployment, health and religious beliefs, low family income, lack of community 
support and integration, poor pre-initiation adherence counselling as some of the factors that contribute to poor 
medication adherence and the consequent rate of default and lost to follow up. Recent innovations using mobile phone 
technologies such as text messaging to improve medication adherence among patients on ART have been examined 
and implemented across many countries of the world including Kenya, Peru, Brazil, Botswana, USA with high quality 
evidence proving the efficacy of weekly SMS reminders to patients in improving adherence to ART when compared 
to standard care, particularly in 3 Randomized Controlled Trials (RCTs) done in Kenya.10-12 
Another study systematically reviewed the scope and effectiveness of phone messaging for HIV/AIDS care 
based on different study designs (RCTs, Intervention studies using other study designs, qualitative and cross-sectional 
surveys) across US, UK, Kenya, Uganda, Botswana, South Africa, Peru, Pakistan among other countries and concluded 
that mobile phone messaging could play an important role in HIV/AIDS care and its use is acceptable.13 However, 
further studies across low, middle and high income countries, scale-up of program evidence in hospitals, including 
cost-effectiveness analysis were recommended.   
This paper describes baseline characteristics of a cohort of 242 Malaysian patients involved in a randomized 
controlled trial. The overall aim of the study was to investigate whether the introduction of mobile phone technology 
(SMS and telephone call reminders) can significantly improve adherence and treatment outcomes among HIV patients 
on ART in Malaysia. The study’s main aim is in line with key activity 6 of strategy 2 in the current drive by Malaysian 
Government to improve adherence to treatment and detection of treatment failure.3     
METHODS AND MATERIALS
A single-blinded Randomized Controlled Clinical Trial was conducted between January and December, 2014 
in Hospital Sungai Buloh.  It is the largest infectious disease hospital and one the foremost reference hospitals in 
Malaysia. It has over 6,000 HIV/AIDS patients on treatment and care, accounting for 35 – 40% of about 17,000+ 
patients currently on Highly Active Antiretroviral Therapy (HAART) in various centres across Malaysia. The centre 
provides a wide range of HIV/AIDS prevention, care and treatment services including diagnostics, pharmaceutical, 
clinical and support services to an average of 1000 HIV-positive patients per year, out of which an average of 400 
- 500 patients are initiated on HAART yearly based on eligibility criteria. It maintains a high standard and quality 
of care based on international best practices and guidelines. It also provides training and research services including 
continuous medical education, specialist training and knowledge management. 
Sample size calculation was done using the formula for calculating sample size in hypothesis testing by comparing 
two means (Lameshow et al., 1990)14 which returned a sample size (n) maximized at 121 per group. Therefore a 
total sample size of 242 was applied for this study.  Patients who were assessed and found to be eligible for ART 
commencement based on 2013 WHO guidelines, and with valid telephone numbers and able to read text messages 
were included in the study and randomized to either of two treatment arms based on simple, complete randomization 
technique in a ratio 1:1 for intervention and control groups, respectively. Written allocation of assignment was sealed 
in individual opaque envelopes marked with study identification numbers which was made available in the study 
clinic to allocate the target number of participants. After consenting to participate (by filling and signing a consent 
form) and meeting the inclusion criteria, screened subjects were enrolled and immediately afterwards were assigned 
to a randomized study arm by the study coordinator opening the sealed envelopes to determine allocation. Random 
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allocation considered and eliminated all forms of possible bias based on the socio-demographic characteristics of 
the clients. Baseline data on socio-demographic factors, clinical symptoms including TB status and Opportunistic 
Infection (OI) index, and adherence behaviour (over 2-4 weeks of adherence preparation and vitamin training) of 
respondents was collected using modified and pre-validated Adults AIDS Clinical Trial Group (AACTG) adherence 
questionnaires. Baseline CD4 count, viral load, weight, full blood count, blood pressure, Liver function and renal 
profile tests were also conducted and recorded. A “Reminder module” which included standardized weekly SMS 
medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled clinic appointments 
(individualized and sent at lunch time), and an average of 90 second lunch hour telephone call reminders a day prior to 
scheduled clinic appointment (in addition to standard care - routine adherence counselling) was delivered consistently 
for 24 weeks to respondents in the intervention group by 2 trained PLHIV (research assistants) while respondents in 
the control group received standard care only. Each patient in the intervention group had a minimum of three (during 
clinic visits at month 1, month 3 and month 6) individual counselling sessions with the research assistants lasting an 
average of 15 minutes per encounter. To ensure confidentiality, typical medication reminder text messages included a 
short slogan in Malay language “Apa khabar”  “Ini untuk menberithau anda ubat” meaning “How are you?” “This is to 
remind you of your medications”. Appointment reminder text message was “Apa khabar”  “Tolong ingat tarikh temu 
janji lusa” meaning “How are you?” “Remember your appointment day after tomorrow” and telephone conversation 
was standardized and short, with the message “Apa khabar”  “Tolong ingat tarikh temu janji besok” meaning “How 
are you?” “Remember your appointment tomorrow”. Patients were not required to provide any responses to the text 
messages. However, a log of text message communications and telephone calls was recorded and kept.
Adherence measurement was repeated at 3 and 6 months follow up using specialized AACTG follow up 
adherence questionnaires while CD4 count, viral load, weight, full blood count and blood pressure measurements 
were repeated at 6 months follow up period.  Data was entered, cleaned and analyzed using SPSS version 22 and R 
software. Descriptive continuous data were presented as means ± standard deviation (SD), while categorical variables 
are presented as counts and percentages. Chi-square tests of independence, Fisher’s exact test, ANOVA and student 
t-test for independent samples were conducted on the data. The differences were considered to be significant at P<.05. 
Written approval for conducting the study was obtained from Universiti Putra Malaysia Ethics committee for 
Human Research and the Malaysian Ministry of Health’s Institutional Review and Ethics Committee, prior to the 
commencement of the study. Written permission for conducting the study was obtained from the Medical Director of 
the hospital to use their clients. 
RESULTS
Table 1 indicated that out of the 242 patients in the sample, 215 (88.8%) of them were males and 27 (11.2%) were 
females. Malays constituted the overall majority (n = 117, 48.3%) of respondents in the sample, 40.5% were Chinese 
(n = 98), 9.1% were Indians (n = 22) and 2.1% (n = 5) were of other minority ethnic origin such as Ibans. The overall 
mean age of respondents in the sample was 33.4 ± 9.2 SD (95% CI: 32.23 – 34.56) years and ranged from 18 to 64 
years. The mean age for males was 33.1 ± 8.7 SD (95% CI: 31.93 – 34.27) years, while the mean age for females was 
35.7 ± 12.3 SD (95% CI: 30.82 – 40.59). The income distribution of respondents showed that an overall majority of 
respondents (n = 188, 73.6%) earned RM 3499 and below, while 26.4% earned above RM 3500. Majority (n = 170, 
70.2%) of the respondents attained educational level of less than bachelor degree while only 74 (29.7%) attained 
bachelor degree and above. Overall, majority (59.9%) of respondents were private organization employees, 14.9% 
were self- employed, and 12.8% were unemployed. Government employees were of relative minority (n = 21, 8.7%) 
while only 9 respondents (3.7%) reported other forms of employment such as students. Slightly over half (52.9%) of 
the respondents lived in urban location, 36% in semi-urban and 11.2% in rural location. 
Females had lower (75.19 ± 24.8) mean baseline adherence compared to males (83.77 ± 17.2). However, this 
difference did not reach statistical significance (t = 1.354, df =240, P=.19). Overall, mean baseline adherence did not 
differ significantly by age group (F (4, 237) = 0.425, P=.79), ethnicity (F (3, 238) = 0.150, P=.93), income distribution 
(F (4, 237) = 0.156, P=.96), education level (t = -1.173, df =240, P=.24) and employment status (F (4, 237) = 1.144, 
P=.33). Patients who resided in semi-urban areas had significantly higher mean baseline adherence (90.90 ± 8.9) 
compared to those who resided in urban (80.25 ± 19.7) and rural (68.93 ± 32.0) locations. 
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Table 1: Baseline adherence rate by sociodemographic factors
  Factors      n (%) Mean baseline adherence    P value
Age category
29yrs and below  102 (42.1)  81.04 ± 18.8    0.790ᶲ
30 – 39yrs  84 (34.7)  84.54 ± 16.0
40 – 49yrs  42 (17.4)  81.55 ± 18.4
50 -59yrs  11 (4.5)  90.73 ± 9.4
60yrs and above  3 (1.2)  83.67 ± 16.3
Gender
Male  215 (88.8)  83.77 ± 17.2    0.185ª
Female  27 (11.1)  75.19 ± 24.8
Ethnicity                    
Malay  117 (48.3)  82.99 ± 18.1    0.930ᶲ      
Chinese  98 (40.5)  83.47 ± 17.0
Indian  22 (9.1)  80.23 ± 19.7
Others  5 (2.1)  77.20 ± 23.2 
Education level
Bachelor degree and above  72 (29.7)  85.89 ± 14.1    0.243ª
Less than Bachelor degree  170 (70.2)  81.51 ± 18.6
Monthly Income (RM)
<1500                                       60 (24.8)  82.20 ± 18.3    0.960ᶲ
1500 – 2499                               57 (23.6)  83.49 ± 16.7
2500 – 3499                               61 (25.2)  80.90 ± 20.1
3500 – 4999  30 (12.4)  84.17 ± 15.9
>5000                                         34 (14.0)  85.00 ± 14. 9
Employment Status
Unemployed  31 (12.8)  81.65 ± 18.9    0.337ᶲ
Self-employed                           36 (14.9)  86.78 ± 13.7
Government employee              21 (8.7)  71.43 ± 28.7
Private organization employee  145 (59.9)  83.49 ± 17.1
Others  9 (3.7)  86.67 ± 13.3
Residential Location
Rural  27 (11.2)  68.93 ± 32.0    0.003ᶲ*
Semi-urban                                87 (35.9)  90.90 ± 8.9
Urban  128 (52.9)  80.25 ± 19.7
Values are mean ± SD
ªValue obtained by student t-test for independent samples.        
ᶲValue obtained by one-way ANOVA test. 
*Significant at P<0.05
As shown in Table 2a, the male-to-female ratio of respondents in both treatment arms was fairly equal and showed 
no statistically significant difference. There were more Malays than Chinese in the intervention group while the 
reverse was observed in the control group. More Indians and other ethnic minorities were observed in the intervention 
group. Respondents in the intervention group were on average about two and a half years younger than those in the 
control group (t = -2.176, df =240, P=.03). There was no significant difference in income distribution (χ² = 8.647, df 
= 4, P=.07), employment distribution (χ² = 3.534, df = 4, P=.47) and residential location (χ² = 1.219, df = 2, P=.54) 
between respondents in the intervention and control groups as indicated in Table 2b. 
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Table 2a: Baseline socio-demographic characteristics of respondents by treatment group
  Factors Intervention group
 (n = 121)
  Control group
      (n = 121)
        P value
Gender
Male 107 (88.4) 108 (89.3) 0.838ª
Female 14 (11.6) 14 (10.7)
Ethnicity
Malay 64 (52.9) 53 (43.8) 0.036ᶲ
Chinese 39 (32.2) 59 (48.8)
Indian 14 (11.6) 8 (6.6)
Others 4 (3.3) 1 (0.8)
Age (yrs) 32.1 ± 8.7                            34.7 ± 9.5                   0.031ᶲ
Education level
Less than Bachelor degree 71 (58.7) 93 (76.9) 0.004ª
Bachelor degree and above 50 (41.3) 28 (23.1)
Monthly Income (RM)
<1500                                        21 (17.4)                              39 (32.2) 0.071ª
1500 – 2499                              29 (24.0) 28 (23.1)
2500 – 3499                              32 (26.4)                              29 (24.0)                     
3500 – 4999 18 (14.8) 12 (9.9)
>5000                                        21 (17.4)                              13 (10.7)
Values are n (%) or mean ± SD. 
ªValue obtained by chi-square test.        
ᶲValue obtained by Fisher’s exact test. 
ᶲValue obtained by student t- test for independent samples.        RM = Ringgit Malaysia 
Table 2b: Baseline socio-demographic characteristics of respondents by treatment group
  Factors Intervention group
        (n = 121)
  Control group
      (n = 121)
        P value
Employment Status
Unemployed 13 (10.7) 18 (14.9) 0.473ª
Self-employed                          19 (15.7)                               17 (14.0)
Government employee             14 (11.6)                               7 (5.8)                        
Private organization employee 70 (57.9)                               75 (61.9)
Others 5 (4.1)                                   4 (3.3)
Residential Location
Rural 11 (9.1)                                 16 (13.2) 0.544ª
Semi-urban                               43 (35.5)                               44 (36.4)                     
Urban 67 (55.4)                               61 (50.4)
Values are n (%) or mean ± SD. 
ªValue obtained by chi-square test.        
Table 3a indicated that overall, 47.9% of respondents were placed on ZDV/3TC/EFV regimen, 47.1% took TDF/FTC/
EFV regimen at baseline (ART initiation) while other HAART regimens accounted for only 5% of the distribution 
altogether. A similar distribution was observed among respondents in both intervention and control group as 
approximately 95% of respondents were placed on either ZDV/3TC/EFV or TDF/FTC/EFV regimen in each group. 
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A 30 day recent history of alcohol use was assessed among respondents. Overall, 195 (80%) out of a total of 242 
patients in the sample never had a drink containing alcohol while the remaining 20% had alcohol at various periods 
and quantities over the last 30 days. 10% of respondents had alcohol once a month while only 1 respondent in the 
control group had alcohol daily. There was no statistically significant difference in history of alcohol use between 
respondents in the intervention and control group (Fisher’s exact P=1.00). 
Previous history of drug use (IDUs and non-IDUs) and frequency of usage over the past 6 months was assessed 
among respondents. As highlighted in Tables 3a and 4, only about 6% of respondents have ever used any recreational 
drug before. 234 (97%) out of a total 242 respondents in the sample never used marijuana, 239 (99%) never used 
cocaine, 237 (98%) never used heroine or opioids, 227 (94%) never used amphetamines in the past while only 3 
(1%) patients were currently on methadone treatment. This pattern was same as observed in the drug use history of 
respondents in both treatment arms, hence, no statistically significant group difference was observed for any of the 
above mentioned drugs in the past.
Based on the information on when a patient last missed their medications and the weighted average of the number 
of doses missed at each time period, participants were further categorized into Good, Fair or Poor adherence levels. As 
indicated in Table 3b, overall, 194 (80%) respondents in the sample had Good adherence while the remaining 20% had 
poor adherence. Among the intervention group, about 77% of respondents had good adherence as compared to 84% 
in the control group. There was no significant difference in the baseline medication adherence levels of respondents in 
the intervention and control groups (χ² = 1.663, df = 1, P=.19).
The overall mean baseline medication adherence was 82.6 ± 17.7 SD for the sample. There was no significant 
difference in the mean baseline medication adherence (80.1 ± 19.6 SD) for the intervention group as compared to the 
control group (85.1 ± 15.8 SD) (t = -1.252, df = 235.6, P=.21). 
It is also explicit from Table 3b that overall, majority (80%) of respondents had disclosed their HIV status to a 
family or close friend, while 36% had at least one comorbidity at baseline. Sexual transmission was the most likely 
mode of HIV transmission in about 91% of respondents who initiated HAART in the current study, followed by other 
modes of transmission predominantly IDUs and blood transfusion accounting for 5%, while about 4% of respondents 
didn’t know the most likely source of infection. Results from the current study indicated that 37% of respondents were 
heterosexuals while 54% were homosexuals and 9% were bisexual. 
About 12% higher proportion of respondents in the control group had disclosed their HIV status to a family or 
close friend (χ² = 5.094, df = 1, P=.02), and reported more comorbidity at baseline (χ² = 8.730, df = 1, P<.01) than the 
intervention group. Although there were slightly more homosexuals in the intervention group than the control group, 
this difference did not reach statistical significance (χ² =4.030, df = 1, P=.26).
In terms of TB status at baseline, overall only about 18% of respondents were either currently on TB treatment 
(4%) or suspected clinically for TB (14%). 83% of respondents had no signs or symptoms of any new OI, 9% were 
Hepatitis B positive while 7% were Hepatitis C positive. There was no statistically significant difference in TB status 
(χ² = 1.731, df = 2, P=.42), OI index (Fisher’s exact P=.28), Hepatitis B (χ² = 1.800, df = 1, P=.18) and Hepatitis C 
status (χ² = 1.071, df = 1, P=.30) between respondents in the intervention group and those in the control group. 
Table 3a: Baseline therapy-related and patient-related factors by treatment group
  Factors Intervention group
        (n = 121)
  Control group
      (n = 121)
      P value
Therapy-related factors
HAART Regimen
ZDV/3TC/NVP                             2 (1.7)                                  5 (4.1)                      1.000ª
ZDV/3TC/EFV 59 (48.8)                              57 (47.1)
TDF/FTC/NVP                             1 (0.8)                                  1 (0.8)
TDF/FTC/EFV                              58 (47.9)                             56 (46.3)
ZDV/3TC/RALTEGRAVIR        1 (0.8)                                  1 (0.8)                                  
D4T/3TC/EFV                              0 (0.0) 1 (0.8)
Patient-related factors
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Alcohol use (past 30 days)
Never 100 (82.6)                             95 (78.5)                  1.000ª
Once a month                                12 (9.9)                                13 (10.7)
2 or 3 times a month                      6 (5.0)                                  7 (5.8)
3 or 4 times a week                        3 (2.5)                                  5 (4.1)
Daily 0 (0.0)                                   1 (0.8)
Drug use history
(a) Marijuana
No 117 (96.7)                             117 (96.7)                             0.639ª
Yes 4 (3.3) 4 (3.3)
(b) Cocaine
No 119 (98.3)                             120 (99.2)                0.500ª
Yes 2 (1.7)                                   1 (0.8)
(c) Heroine
No 120 (99.2)                             117 (96.7) 0.185ª
Yes 1 (0.8) 4 (3.3)
(d) Amphetamines
No 115 (95.0)                             112 (92.6)                0.424ᶲ
Yes 6 (5.0)                                   9 (7.4)
(e) Opioids
No 118 (97.5)                             119 (98.3)                 0.500ª
Yes 3 (2.5)                                   2 (1.7)
(f) Methadone treatment
No 119 (98.3)                             120 (99.2)                 0.500ª
Yes 2 (1.7)                                   1 (0.8)
Values are n (%) or mean ± SD. 
ªValue obtained by Fisher’s exact test.        
ᶲValue obtained by chi-square test. 
ᶲValue obtained by student t- test for independent samples. 
Table 3b: Baseline medication adherence, condition and treatment-related factors by treatment group
  Factors Intervention group
        (n = 121)
 Control group
      (n = 121)
   P value
Treatment-related factors
When patient last missed medications
Not at all                                       93 (76.9)                               101 (83.5)                 0.745ª
1-3 months ago                             1 (0.8)                                   1 (0.8)                                   
2-4 weeks ago                               4 (3.3)                                   2 (1.7)
1-2 weeks ago                               6 (5.0)                                   5 (4.1)
Within the past week           17 (14.0)  12 (9.9)
Mean adherence                          80.1 ± 19.6                           85.1 ± 15.8                0.212ᶲ
Baseline medication adherence level
Poor adherence                             28 (23.1)                               20 (16.5)                    0.197ᶲ
Good adherence                             93 (76.9)                               101 (83.5)
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Condition-related factors
Disclosure status
No 31 (25.6)                             17 (14.0)                     0.024ª
Yes 90 (74.4)                             104 (86.0)
Most likely source of HIV infection
Don’t know                                            4 (3.3)                                  6 (5.0) 0.158ª
Others (IVDU, blood transfusion) 3 (2.5)                                  9 (7.4)                        
Sexual transmission                             114 (94.2)                            106 (87.6)
TB Status
No signs and symptoms of TB               103 (85.1)                            96 (79.3) 0.421ª
TB suspect                                              13 (10.7)                              20 (16.5)                   
Currently on TB treatment                      5 (4.1)                                   5 (4.1)
OI Index
No signs & symptoms of any new OI    103 (85.1)  97 (80.2)    0.283ᶲ
1 or more WHO stage 2 defining disease      1 (0.8) 1 (0.8)
1 or more WHO stage 3 defining disease      8 (6.6)                                  5 (4.1)
1 or more WHO stage 4 defining disease      9 (7.4)                                  18 (14.9)
Hepatitis B status
Negative 107 (88.4)                            113 (93.4)                   0.180ª
Positive 14 (11.6)                              8 (6.6)
Hepatitis C status
Negative 115 (95.0)                            111 (91.7)                   0.301ª
Positive 6 (5.0)                                  10 (8.3)
Values are n (%) or mean ± SD. 
ªValue obtained by Fisher’s exact test.        
ᶲValue obtained by chi-square test. 
ᶲValue obtained by student t- test for independent samples. 
Table 4 also indicated that mean baseline adherence did not differ significantly by respondents’ source of HIV infection 
(F (2, 239) = 0.448, P=.64), sexual orientation (F (2, 239) = 0.309, P=.82), disclosure status (t (240) = 1.131, P=.26), 
alcohol (F (4, 237) = 1.134, P=.34) and drug use history. 
Notably, patients who acquired HIV infection through Intravenous Drug Use and blood transfusion had lowest 
mean baseline adherence of 77.08 ± 12.9. Whereas there were more homosexuals than heterosexuals and bisexuals in 
the sample, mean baseline adherence was fairly similar among these three groups. A higher mean baseline adherence 
(83.82 ± 16.1) was observed among respondents who had disclosed their HIV status to a friend or family member, as 
compared to those who had not. However, this difference did not reach statistical significance. 
Interestingly, and perhaps expectedly, an optimal (>95%) and highest mean baseline adherence was observed 
among respondents who were currently on TB treatment as compared to those who were TB suspects (90.79 ± 9.2) 
or patients who had no signs and symptoms of TB (80.83 ± 19.1). This difference was however not statistically 
significant.
We observed that mean baseline adherence was higher among patients who used alcohol more frequently, 
although this difference did not reach statistical significance. With the exception of 13 patients who used opioids and 
marijuana, we found a sub-optimal and similar mean baseline adherence of 77.41 ± 22.5 for patients on methadone 
replacement and positive history of cocaine, heroine and amphetamine use. 
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Table 4: Baseline adherence rate by patient-related and condition-related factors
  Factors    n (%) Mean baseline adherence    P value
Most likely source of HIV infection
Don’t know                                             10 (4.1)  88.30 ± 12.2    0.640ᶲ
Others (IVDU, blood transfusion)  12 (4.9)  77.08 ± 12.9                        
Sexual transmission                              220 (90.9)  82.88 ± 17.3
Sexual orientation
Homosexual  131 (54.1)  82.59 ± 18.0    0.819ᶲ
Heterosexual  89 (36.8)  83.30 ± 16.8
Bisexual  22 (9.1)  82.69 ± 17.3
Transgender  0 (0.0)  -
Disclosure status
No 48 (19.8)  78.75 ± 21.2    0.259ª
Yes 194 (80.1)  83.82 ± 16.1
TB Status
No signs and symptoms of TB               199 (82.2)  80.83 ± 19.1    0.050ᶲ
TB suspect                                              33 (13.6)  90.79 ± 9.2
Currently on TB treatment                      10 (4.1)  96.00 ± 4.1
History of alcohol use (past 30 days)
Never  195 (80.6)  84.22 ± 16.3    0.341ᶲ
Once a month  25 (10.3)  76.20 ± 13.8
2 or 3 times a month  13 (5.4)  71.23 ± 28.9
3 or 4 times a week  8 (3.3)  86.38 ± 13.6
Daily  1 (0.4)  96.00
Drug use history
(a) Marijuana
No  234 (96.7)  82.85 ± 17.1    0.902ª
Yes  8 (3.3)  81.63 ± 18.3
(b) Cocaine
No  239 (98.8)  82.89 ± 17.3    0.716ª
Yes  3 (1.2)  77.00 ± 22.9
(c) Heroine
No  237 (97.9)  82.92 ± 17.5    0.685ª
Yes  5 (2.1)  77.80 ± 22.1
(d) Amphetamines
No  227 (93.8)  83.14 ± 16.8    0.478ª
Yes  15 (6.2)  77.87 ± 22.1
(e) Opioids
No  237 (97.9)  82.54 ± 18.0    0.285ª
Yes  5 (2.1)  96.00 ± 3.9
(f) Methadone treatment
No  239 (98.8)  82.89 ± 18.1    0.716ª
Yes  3 (1.2)  77.00 ± 22.9
Values are mean ± SD.  ªValue obtained by student t-test for independent samples; ᶲone-way ANOVA.        
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Table 5 below showed that the overall mean CD4 cell count for the sample was 222.98 ± 143.7 SD. The mean CD4 
count of respondents in the intervention group was 232.64 ± 137.9 SD and was not significantly higher than that of the 
control group (213.31 ± 149.4 SD) (t = 1.046, df = 240, P=.29).  
Mean viral load log for the sample was 4.73 ± 1.0 SD. In the intervention group, the mean viral load log was 
4.61 ± 0.9 which was slightly lower than that of the control group (4.85 ± 1.1 SD). There was no significant difference 
in the mean viral load log between respondents in the intervention and control groups (t = -1.465, df = 240, P=.14). 
The overall mean weight of respondents at baseline was 61.33 ± 11.9 SD. There was no significant difference 
between the mean weight of respondents in the intervention group (61.19 ± 11.4 SD) compared to that of respondents 
in the control group (61.47 ± 12.3 SD) (t = 0.056, df = 240, P=.96). 
Table 5:  Baseline CD4 count, Viral Load and weight of respondents
  Factors Intervention group
        (n = 121)
  Control group
      (n = 121)
        P value
CD4 count (cells/µl) 232.64 ± 137.9                             213.31 ± 149.4                        0.297
Viral Load (Log10)             4.61 ± 0.9                                     4.85 ± 1.1                                0.144
Weight (Kg)                  61.19 ± 11.4                                 61.47 ± 12.3                            0.955
Values are mean ± SD. 
Values obtained by student t- test for independent samples. 
DISCUSSION
The mean age (in years) of 242 respondents was 33.4 ± 9.2 SD (58% were of the age group 30-39 years) which 
is similar to the findings of previous studies in Malaysia,1,2  Kenya11 and Brazil.15  According to WHO, poverty 
is a significant determinant of disease occurrence. Very few studies have identified poor financial incentives that 
include out-of-pocket expenses and high transportation costs from frequent hospital visits as some of the factors that 
contribute to non-adherence. These may explain why patients from rural areas had poorer adherence as shown in this 
study. Thrice as many respondents in the current study as in a similar study in Kelantan, Malaysia earned RM 1,500 
and above. The reverse was true for those who earned below RM 1,500. This is perhaps due to geographical variation 
in earning capacity and cost of living between residents of Kelantan and Selangor, Malaysia which may potentially 
affect adherence. Despite this distribution, we found that among patients initiating ART in Selangor, mean adherence 
at baseline was not dependent on patient’s income status.    
We found about five times as many persons in Selangor as Kelantan16 attended tertiary education and also had 
higher mean baseline adherence. This population of PLHIV graduates is also 43% higher than what was reported 
elsewhere in Botswana.17 State-specific socio-economic and cultural dynamics which influence access and affordability 
of tertiary education between and among populations, may explain these variations. However, our study as above also 
showed that educational level does not have significant effect on baseline adherence. 
The correlation between employment status, available monthly income (to cover transportation costs for clinic 
follow up visits, adequate nutrition and any incidental out-of-pocket expenses) and adherence to treatment (regular 
clinic follow up visits and strict medication adherence) has been widely reported in literature. Our study found 
that 83% of respondents in the sample were employed (either self-employed, Government or private organization 
employees) while 17% were unemployed. These findings represent much higher values than that reported in Kelantan 
but not Bostwana. However, our study also showed that baseline adherence is not significantly affected by patient’s 
employment status. Exploring the interplay of socio-economic and other developmental factors that influence job 
availability and income distribution becomes a useful planning tool for health interventions.
A similar intervention study in Kenya11 reported higher proportion of urban dwellers in the sample than the 
current study which also had 36% semi-urban dwellers. Interestingly, we found in this study, a significantly higher 
mean baseline adherence among semi-urban dwellers than urban and rural dwellers. While poor access to information 
and low education level may perhaps explain why rural dwellers had the poorest adherence in this study, it appears 
that targeted, integrated health interventions to address low income, access to information, education and qualitative 
adherence counselling among rural dwellers would be most beneficial.     
                                                 
Abdulrahman Surajudeen Abiola,¹Lekhraj Rampal,¹ Norlijah Othman, Faisal Ibrahim,¹
Hayati Kadir@Shahar,¹Anuradha P. Radhakrishnan²
55
Malaysian Journal of Medicine and Health Sciences Vol. 11 (2) June 2015 Malaysian Journal of Medicine and Health Sciences Vol. 11 (2) June 2015
To the best of our knowledge, this is the first study to assess and report medication adherence among HIV positive 
patients receiving ART in Malaysia. Our study utilized a standardized, modified AACTG adherence questionnaire18 
to measure medication adherence by self-report. The overall mean adherence at baseline was 82.6 ± 17.7 SD. This is 
not only consistent with previous evidence from studies with varying designs from rural Uganda19 to Urban United 
States20 or even China21 but also provides new evidence in a concentrated epidemic like Malaysia. Much fewer studies 
in low-to-middle income countries, predominantly observational, have reported higher baseline mean adherence than 
the current study.22,23 Apart from differences in socio-demographic characteristics of respondents which may explain 
the observed similarities and/or differences in results between our study and those highlighted above, there was also 
significant difference in the study population in terms of duration on ART treatment. While our study utilized ART-
naïve patients at baseline, both Ugandan studies above recruited patients who had been on ART for a period between 
0-3 years. 
Decision-making by HIV clinicians on when to initiate ART among HIV positive patients is usually based on 
clinical (WHO staging) and immunological parameters (CD4 count) of the patients at baseline. According to WHO 
(2013),24 ART should be initiated among HIV positive patients in WHO clinical stage 1 and 2 whose CD4 count is 
≤500 cells/mm³ (CD4 ≤350 cells/mm³ as a priority). It also recommended ART commencement among patients with 
severe or advanced HIV disease (WHO clinical stage 3 and 4) irrespective of their CD4 count. In the current study, 
the overall mean CD4 count of respondents at baseline was 222.98 ± 143.7 SD. No significant group differences were 
observed.  Much higher figures have been previously reported in intervention studies in United States25 and China21 
but not in African studies11,17 where majority of patients appear to initiate ART at generally lower CD4 count due to 
higher burden and limited access to ART. As evidence continues to influence practice (EBM), it will not be surprising 
to see newer studies reporting higher pre-initiation CD4 count based on 2013 WHO guidelines than earlier studies 
conducted based on 2010 WHO guidelines. 
Although results of viral load test at baseline are not critical to decision-making on when to initiate ART, the 
value of viral load monitoring in diagnosing treatment failure and deciding when to switch to second-line ART or 
salvage therapy cannot be over-emphasized. HIV clinicians where feasible, have however measured and compared 
baseline viral load test results with those repeated after 4-6 months of antiretroviral therapy in deciding whether a 
patient has achieved viral suppression or not. In the clinical setting where the current research was conducted, it is 
routine practice for clinicians to order for viral load test among other investigations at baseline, for every HIV positive 
patient commencing ART.  Typical viral load test results in this setting are reported as absolute viral load counts per 
mL of blood as well as log10 copies per mL of blood. The overall mean viral load count in the current study was 
252662.74 ± 528133.95 SD. Twice higher pre-initiation viral load was previously reported in United States25 than in 
Malaysia, Botswana17 and Kenya.11 Perhaps, differences in clinical stage and biomedical parameters of patients at 
initiation of ART may explain these variations.
We found a much higher mean weight of respondents at baseline (61.33 ± 11.9 SD) kg than a similar study 
in rural Rwanda,26 and although BMI measurement was beyond the scope of the current study, values lower than 
Malaysian national average were reported in Tanzania27 and Kenya.28 No significant group differences in weight 
distribution of respondents was found in our study. Differences in the respondents’ clinical stage at presentation may 
explain this variations. 
With the implementation of WHO STOP-TB strategy and integration of TB/HIV services in the clinical setting 
in which our study was conducted, an improved TB case detection rate was not unexpected. In the current study, 
overall, only about 18% of respondents were either currently on TB treatment (4%) or suspected clinically for TB 
(14%) while 82% had no signs and symptoms of TB at baseline. Our study found a TB-HIV co-infection rate of 4.1% 
among respondents in each of the intervention and control groups. These results although slightly lower, are consistent 
with the 2013 TB-HIV co-infection rate of 6.1% reported by 2014 Malaysia Global AIDS Response Country Progress 
Report [1] and from a clinical setting in India29 of 4.85%. As much as four to ten-fold higher TB-HIV co-infection 
rates have been reported in rural Rwanda26 and among TB suspects in Kenya,30 respectively.  Relative differences in 
National programme focus as well as level of availability and access to TB-HIV diagnostic services may explain the 
observed continental variations. 
We found optimal (>95%) baseline adherence among all the TB-HIV co-infected patients in our sample compared 
to previous similar studies reporting up to 56% non-adherence among co-infected patients in other developing countries 
such as Uganda, Nigeria and Ethiopia.31 - 33     
In the setting of the current study, respondents in the sample were assessed for opportunistic infections at 
baseline and during each follow up visit. Overall, about 4 in 5 respondents were free of any OIs at baseline. Same was 
the case in both treatment arms. These results are similar to the findings of a similar study conducted in Tanzania27 in 
which about 24% of respondents had one or more symptoms and signs of WHO stage 2, stage 3 or stage 4 defining 
diseases at baseline. Due to enormity of possible opportunistic infections among HIV positive patients, it is often 
difficult for studies to track and report effectively on these conditions, hence the paucity of data on OI index of patients 
at baseline, in literature.
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This study has some important limitations. In addition to the fact that self-report of adherence behaviour is 
widely believed to over-estimate true adherence, baseline adherence scores presented in this study might have been 
further exaggerated by estimating adherence behaviour based on 2 – 4 weeks of vitamin training (with little or no side 
effects) and adherence preparation prior to ART initiation, and not necessarily HAART.   
CONCLUSION
Overall, the cohort of 242 patients involved in this trial were largely males (88.8%), with a mean age of 33.1 (95% 
CI: 31.93 – 34.27) years but higher mean baseline adherence than females. Semi-urban dwellers had higher baseline 
adherence than urban and rural dwellers. Mean baseline adherence of participants in the sample did not differ by 
other socio-demographic, patient or condition-related factors. However, significant group differences in the mean 
age, ethnic distribution and education level of participants was observed between treatment arms. On the average, this 
cohort initiated ART at suboptimal baseline adherence, low CD4 count and high viral load, with about 20% of patients 
needing adherence interventions from the outset, in addition to routine strategic and collaborative treatment adherence 
planning between the patient and the care-giver before commencement of and during the course of ART, in order to 
achieve successful treatment outcomes.
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